Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday

by · The Cerbat Gem

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) is expected to announce its Q4 2025 results before the market opens on Monday, December 22nd. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, November 25, 2025 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last released its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. During the same period last year, the company posted ($0.14) earnings per share. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Down 5.7%

NASDAQ AVXL opened at $3.67 on Friday. Anavex Life Sciences has a 12-month low of $2.86 and a 12-month high of $14.44. The stock has a market capitalization of $327.91 million, a PE ratio of -6.80 and a beta of 1.15. The company has a 50 day moving average price of $5.88 and a two-hundred day moving average price of $8.43.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AVXL. Jones Trading cut shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Wall Street Zen cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anavex Life Sciences in a research note on Monday, December 15th. D. Boral Capital reiterated a “buy” rating on shares of Anavex Life Sciences in a research report on Monday, December 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Anavex Life Sciences in a report on Friday, November 28th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Anavex Life Sciences presently has an average rating of “Hold” and an average target price of $44.00.

Check Out Our Latest Stock Analysis on Anavex Life Sciences

Hedge Funds Weigh In On Anavex Life Sciences

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. increased its position in shares of Anavex Life Sciences by 55.8% during the second quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company’s stock worth $7,966,000 after acquiring an additional 309,605 shares in the last quarter. XTX Topco Ltd acquired a new position in Anavex Life Sciences in the 3rd quarter worth $727,000. Two Sigma Investments LP increased its holdings in Anavex Life Sciences by 6.5% during the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock worth $9,229,000 after purchasing an additional 63,685 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of Anavex Life Sciences by 14.0% in the 3rd quarter. Private Advisor Group LLC now owns 455,125 shares of the biotechnology company’s stock valued at $4,051,000 after purchasing an additional 55,900 shares during the period. Finally, Verition Fund Management LLC raised its stake in shares of Anavex Life Sciences by 109.8% in the 3rd quarter. Verition Fund Management LLC now owns 68,859 shares of the biotechnology company’s stock valued at $613,000 after purchasing an additional 36,039 shares during the period. 31.55% of the stock is currently owned by institutional investors and hedge funds.

About Anavex Life Sciences

(Get Free Report)

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.

Read More